Last year David Liu, who already had ~20 million shares of $PRME, purchased another 84,000 shares OTC. This guys is basically the father of modern gene editing. Will be shocked if he doesn’t win Nobel prize for his work.
Here is another ground breaking research from Prof. @davidrliu - from Harvard & @broadinstitute and the co-invetor of Base Editing - $BEAM & Prime Editing - $PRME, in which a new all-RNA lipid nanoparticle (LNP) delivery platform for efficient In Vivo Prime Editing (PE) was introduced 🧵👇. Genetic delivery is by far the biggest challenge and scientific bottleneck which prevents Gene Therapy, CRISPR & other Gene Editing platforms - such as Base Editing & Prime Editing, from curing thousands of genetic diseases. The importance of these new findings - identifying bottlenecks in Prime Editor delivery, developing a workflow for LNP optimization and using it to rescue a mouse model of phenylketonuria, are critical to overcome the genetic delivery challenge.
$PRME Program Updates
Wilson’s Disease IND on track for 1H 2026 • AATD IND on track for mid-2026.
PRME remains the only gene editing company heading into the clinic for Wilson’s Disease.
There is one gene editing company for CF (presumably Intellia-Recode), but has not heard much about their progress.